Mutational Patterns Associated with the 69 Insertion Complex in Multi-drug-resistant HIV-1 Reverse Transcriptase that Confer Increased Excision Activity and High-level Resistance to Zidovudine

Journal of Molecular Biology

Volumn 365, Issue 2, 2007, Pages 298-309

  Cases González, Clara E ^a   Franco, Sandra ^b   Martínez, Miguel Ángel ^b   Menéndez Arias, Luis ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

drug resistance; HIV; reverse transcriptase; thymidine analogues; zidovudine

Indexed keywords

DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SENSITIVITY; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DOMAIN; SITE DIRECTED MUTAGENESIS; WILD TYPE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33751552155     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2006.09.073     Document Type: Article

References (61)

1. Telesnitsky A., and Goff S.P. Reverse transcriptase and the generation of retroviral DNA. In: Coffin J., Hughes S.H., and Varmus H.E. (Eds). Retroviruses (1997), Cold Spring Harbor Laboratory Press, Plainview, NY 121-160
2. Castro H.C., Loureiro N.I.V., Pujol-Luz M., Souza A.M.T., Albuquerque M.G., Santos D.O., et al. HIV-1 reverse transcriptase: a therapeutical target in the spotlight. Curr. Med. Chem. 13 (2006) 313-324
3. Menéndez-Arias L. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol. Sci. 23 (2002) 381-388
4. De Clercq E. Antivirals and antiviral strategies. Nature Rev. Microbiol. 2 (2004) 704-720
5. Menéndez-Arias L., Matamoros T., Deval J., and Canard B. Molecular mechanisms of resistance to nucleoside analogue inhibitors of human immunodeficiency virus reverse transcriptase. Drug Design Rev. (On line) 2 (2005) 101-113
6. Vivet-Boudou V., Didierjean J., Isel C., and Marquet R. Nucleoside and nucleotide inhibitors of HIV-1 replication. Cell. Mol. Life Sci. 63 (2006) 163-186
7. Sarafianos S.G., Das K., Clark Jr. A.D., Ding J., Boyer P.L., Hughes S.H., and Arnold E. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids. Proc. Natl Acad. Sci. USA 96 (1999) 10027-10032
8. Meyer P.R., Matsuura S.E., Mian A.M., So A.G., and Scott W.A. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4 (1999) 35-43
9. Meyer P.R., Matsuura S.E., Schinazi R.F., So A.G., and Scott W.A. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates. Antimicrob. Agents Chemother. 44 (2000) 3465-3472
10. Boyer P.L., Sarafianos S.G., Arnold E., and Hughes S.H. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 75 (2001) 4832-4842
11. Lennerstrand J., Hertogs K., Stammers D.K., and Larder B.A. Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants. J. Virol. 75 (2001) 7202-7205
12. Naeger L.K., Margot N.A., and Miller M.D. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antivir. Ther. 6 (2001) 115-126
13. Meyer P.R., Matsuura S.E., Tolun A.A., Pfeifer I., So A.G., Mellors J.W., and Scott W.A. Effect of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 46 (2002) 1540-1545
14. Meyer P.R., Smith A.J., Matsuura S.E., and Scott W.A. Effects of primer-template sequence on ATP-dependent removal of chain terminating nucleotide analogues by HIV-1 reverse transcriptase. J. Biol. Chem. 279 (2004) 45389-45398
15. Naeger L.K., Margot N.A., and Miller M.D. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 46 (2002) 2179-2184
16. Mas A., Vázquez-Álvarez B., Domingo E., and Menéndez-Arias L. Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors. J. Mol. Biol. 323 (2002) 181-197
17. Tong W., Lu C.-D., Sharma S.K., Matsuura S., So A.G., and Scott W.A. Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase. Biochemistry 36 (1997) 5749-5757
18. Marchand B., and Götte M. Site-specific footprinting reveals differences in the translocation status of HIV-1 reverse transcriptase - Implications for polymerase translocation and drug resistance. J. Biol. Chem. 278 (2003) 35362-35372
19. De Antoni A., Foli A., Liscziewicz J., and Lori F. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J. Infect. Dis. 176 (1997) 899-903
20. Winters M.A., Coolley K.L., Girard Y.A., Levee D.J., Hamdan H., Shafer R.W., et al. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J. Clin. Invest. 102 (1998) 1769-1775
21. Winters M.A., and Merigan T.C. Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms. Antimicrob. Agents Chemother. 49 (2005) 2575-2582
22. Menéndez-Arias L., Matamoros T., and Cases-González C.E. Insertions and deletions in HIV-1 reverse transcriptase: consequences for drug resistance and viral fitness. Curr. Pharm. Des. 12 (2006) 1811-1825
23. Van Vaerenbergh K., van Laethem K., Albert J., Boucher C.A.B., Clotet B., Floridia M., et al. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob. Agents Chemother. 44 (2000) 2109-2117
24. Parikh U.M., Bacheler L., Koontz D., and Mellors J.W. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J. Virol. 80 (2006) 4971-4977
25. Mas A., Parera M., Briones C., Soriano V., Martínez M.A., Domingo E., and Menéndez-Arias L. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO J. 19 (2000) 5752-5761
26. Prado J.G., Franco S., Matamoros T., Ruiz L., Clotet B., Menéndez-Arias L., et al. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. Virology 326 (2004) 103-112
27. Matamoros T., Franco S., Vázquez-Álvarez B.M., Mas A., Martínez M.A., and Menéndez-Arias L. Molecular determinants of multi-nucleoside analogue resistance in HIV-1 reverse transcriptases containing a dipeptide insertion in the fingers subdomain - Effect of mutations D67N and T215Y on removal of thymidine nucleotide analogues from blocked DNA primers. J. Biol. Chem. 279 (2004) 24569-24577
28. Boyer P.L., Sarafianos S.G., Arnold E., and Hughes S.H. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision. J. Virol. 76 (2002) 9143-9151
29. Harrigan P.R., Montaner J.S.G., Wegner S.A., Verbiest W., Miller V., Wood R., and Larder B.A. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 15 (2001) 1671-1677
30. Qari S.H., Respess R., Weinstock H., Beltrami E.M., Hertogs K., Larder B.A., et al. Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. J. Clin. Microbiol. 40 (2002) 31-35
31. Ray A.S., Murakami E., Basavapathruni A., Vaccaro J.A., Ulrich D., Chu C.K., et al. Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. Biochemistry 42 (2003) 8831-8841
32. Sarafianos S.G., Clark Jr. A.D., Das K., Tuske S., Birktoft J.J., Ilankumaran P., et al. Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J. 21 (2002) 6614-6624
33. Huang H., Chopra R., Verdine G.L., and Harrison S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282 (1998) 1669-1675
34. Meyer P.R., Matsuura S.E., So A.G., and Scott W.A. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl Acad. Sci. USA 95 (1998) 13471-13476
35. Deval J., Alvarez K., Selmi B., Bermond M., Boretto J., Guerreiro C., et al. Mechanistic insights into the suppression of drug resistance by human immunodeficiency virus type 1 reverse transcriptase using α-boranophosphate nucleoside analogs. J. Biol. Chem. 280 (2005) 3838-3846
36. Sarafianos S.G., Pandey V.N., Kaushik N., and Modak M.J. Site-directed mutagenesis of arginine 72 of HIV-1 reverse transcriptase - Catalytic role and inhibitor sensitivity. J. Biol. Chem. 270 (1995) 19729-19735
37. Kaushik N., Harris D., Rege N., Modak M.J., Yadav P.N.S., and Pandey V.N. Role of glutamine-151 of human immunodeficiency virus type-1 reverse transcriptase in RNA-directed DNA synthesis. Biochemistry 36 (1997) 14430-14438
38. Harris D., Kaushik N., Pandey P.K., Yadav P.N.S., and Pandey V.N. Functional analysis of amino acid residues constituting the dNTP binding pocket of HIV-1 reverse transcriptase. J. Biol. Chem. 273 (1998) 33624-33634
39. Mewshaw J.P., Myrick F.T., Wakefield D.A.C.S., Hooper B.J., Harris J.L., McCreedy B., and Borroto-Esoda K. Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. J. Acquir. Immune Defic. Syndr. 29 (2002) 11-20
40. Maeda Y., Venzon D.J., and Mitsuya H. Altered drug sensitivity, fitness and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J. Infect. Dis. 177 (1998) 1207-1213
41. Kosalaraksa P., Kavlick M.F., Maroun V., Le R., and Mitsuya H. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay. J. Virol. 73 (1999) 5356-5363
42. Larder B.A., Bloor S., Kemp S.D., Hertogs K., Desmet R.L., Miller V., et al. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob. Agents Chemother. 43 (1999) 1961-1967
43. Meyer P.R., Lennerstrand J., Matsuura S.E., Larder B.A., and Scott W.A. Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation. J. Virol. 77 (2003) 3871-3877
44. Nikolenko G.N., Palmer S., Maldarelli F., Mellors J.W., Coffin J.M., and Pathak V.K. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc. Natl Acad. Sci. USA 102 (2005) 2093-2098
45. Smith A.J., and Scott W.A. The influence of natural substrates and inhibitors on the nucleotide-dependent excision activity of HIV-1 reverse transcriptase in the infected cell. Curr. Pharm. Des. 12 (2006) 1827-1841
46. Petropoulos C.J., Parkin N.T., Limoli K.L., Lie Y.S., Wrin T., Huang W., et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44 (2000) 920-928
47. Lin P.-F., Samanta H., Rose R.E., Patick A.K., Trimble J., Bechtold C.M., et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J. Infect. Dis. 170 (1994) 1157-1164
48. Izopet J., Bicart-See A., Pasquier C., Sandres K., Bonnet E., Marchou B., et al. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine. J. Med. Virol. 59 (1999) 507-511
49. Coakley E.P., Gillis J.M., and Hammer S.M. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 14 (2000) F9-F15
50. Calvez V., Costagliola D., Descamps D., Yvon A., Collin G., Cécile A., et al. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. Antivir. Ther. 7 (2002) 211-218
51. Yahi N., Tamalet C., Tourrés C., Tivoli N., Ariasi F., Volot F., et al. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. J. Clin. Microbiol. 37 (1999) 4099-4106
52. Hanna G.J., Johnson V.A., Kuritzkes D.R., Richman D.D., Leigh-Brown A., Savara A.V., et al. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J. Infect. Dis. 181 (2000) 904-911
53. Hu Z., Giguel F., Hatano H., Reid P., Lu J., and Kuritzkes D.R. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J. Virol. 80 (2006) 7020-7027
54. Svicher V., Sing T., Santoro M.M., Forbici F., Rodríguez-Barrios F., Bertoli A., et al. Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J. Virol. 80 (2006) 7186-7198
55. Marcelin A.-G., Delaugerre C., Wirden M., Viegas P., Simon A., Katlama C., and Calvez V. Thymidine analogue reverse transcriptase inhibitors resistance mutation profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J. Med. Virol. 72 (2004) 162-165
56. Martín-Hernández A.M., Domingo E., and Menéndez-Arias L. Human immunodeficiency virus type 1 reverse transcriptase: role of Tyr115 in deoxynucleotide binding and misinsertion fidelity of DNA synthesis. EMBO J. 15 (1996) 4434-4442
57. Menéndez-Arias L. Studies on the effects of truncating α-helix E′ of p66 human immunodeficiency virus type 1 reverse transcriptase on template-primer binding and fidelity of DNA synthesis. Biochemistry 37 (1998) 16636-16644
58. Martín-Hernández A.M., Gutiérrez-Rivas M., Domingo E., and Menéndez-Arias L. Mispair extension fidelity of human immunodeficiency virus type 1 reverse transcriptases with amino acid substitutions affecting Tyr115. Nucl. Acids Res. 25 (1997) 1383-1389
59. Gutiérrez-Rivas M., Ibáñez A., Martínez M.A., Domingo E., and Menéndez-Arias L. Mutational analysis of Phe160 within the "palm" subdomain of human immunodeficiency virus type 1 reverse transcriptase. J. Mol. Biol. 290 (1999) 615-625
60. Kellam P., and Larder B.A. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38 (1994) 23-30
61. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20 (1988) 309-321